Miguel Perales MD

We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List.

bit.ly/4nefIFv

Congratulations to this year’s recipients of the MSK 2025 Paul Marks Prize for Cancer Research: Dr. @oawlab.bsky.social, of MSK; Dr. Andrea Ablasser, of EPFL; and Dr. Christina Curtis, of @stanfordmedicine.bsky.social.

Learn more about the winners: bit.ly/47y8HLb

🚨The FDA approved durvalumab in combination with a chemotherapy regimen before & after surgery for people with early stage #gastriccancer and gastroesophageal #cancers. Congrats to Yelena Janjiagian, who led the trial that resulted the approval! @mskcancercenter.bsky.social

➡️ bit.ly/480s8MO

Memorial Sloan Kettering Cancer Center Applauds Highly Cited Researchers 2025 In 2025, MSK was again ranked among the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers, published...

#ICYMI: 36 MSK researchers are among the @clarivateag.bsky.social list of Highly Cited Researchers 2025, which identifies scientists who have demonstrated significant and broad influence in their field(s) of research.

Admission to the PhD Programs Gerstner Sloan Kettering offers a unique opportunity to train with some of the world’s leading researchers while developing a deep understanding of today’s clinical challenges. We are looking for high...

🚨 Last call: The deadline to apply for the Cancer Biology or Cancer Engineering #PhD programs at MSK's Gerstner Sloan Kettering Graduate School of Biomedical Sciences is 12/1.

Don't miss the opportunity to make the next groundbreaking discovery in cancer and biomedical sciences. Apply ⬇️

Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.

🚨: A clinical trial that resulted in a new @fda.gov approval, led by Dr. Yelena Janjigian, investigated using the immunotherapy treatment #durvalumab (INFINZI) in combination w/a standard-of-care chemotherapy regimen before & after surgery for people w/stomach & esophagus cancer.

bit.ly/3XVQC3G

Healthcare Workers vs Hunger Healthcare workers vs Hunger is an annual friendly competition between teams of healthcare workers to help relieve food insecurity.

5 years ago I started a team competition on Twitter to raise $ to fight hunger.

@tmprowell.bsky.social gave us a hashtag & much needed organization

Our team of teen volunteers work wonders in the background & we’ve raised >$3.1 million!

Competition starts tomorrow, join us?

HCWvsHunger.org

This is amazing!

Your go-to social media guide for #ASH25 is here. Find tips on following updates, taking part in conversations, using the official hashtags, and entering fun challenges with #ASHNewsDaily.

Read now: https://ow.ly/tEgJ50XxAP6

#HemeSky #ASHaiku #ASHKudos #ASHRunWalk #ASHScavengerHunt

Summer Undergraduate Research Experience | HHMI The Cech Fellows Program is a paid, nine-week summer research experience empowering the next generation of scientific leaders.

Calling all rising juniors & seniors: Interested in biological or biomedical research? Applications for our ’26 Summer Undergraduate Research Experience Program are now open! Nine weeks, hands-on research, & mentorship from some of the nation’s top scientists — learn more: bit.ly/CechFellows

Notice from @nysdoh.bsky.social #vaccinessavelives

Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e

Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings.

Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m

The New England Journal of Medicine Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine A Research Summary based on Fitz-Patrick D et al. | 10.1056/NEJMoa2416779 | Published on November 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

Influenza remains an important cause of illness and death. In a phase 3 trial, a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary: nej.md/43udoTG

For 40+ years, the ASH Scholar Award has helped jumpstart careers in hematology—funding 678 awards, $82M in research, and $3B in follow-on funding. Learn more: https://bit.ly/4idJLvV

#ASHAwards

Explore everything #ASH25 has to offer beyond the program! 

Update your headshot 🩸Get the latest in education and fASHion at the ASH Store 👗📚 

Connect in lounges and networking spaces 🤝💬 

Have fun 🎉and rest 😌🛋️! 

🔗On-site amenities: https://ow.ly/Cs9r50XsOEa 

#HemeSky #MedSky #Hematology  

Last chance to submit your comment! Public comments for draft recommendations for myelofibrosis close on November 24.

Learn more: https://ow.ly/ukja50Xf62F

Join Dr. Sewaralthahab to explore the classical hematology sessions sure to have a full house — including a guidelines session, abstract presentation, and Education Program session.

🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/H3mi50XvNJJ #HemeSky #MedSky

6/6

Immunotherapies stand out as a defining theme of #ASH25. @majorajay.bsky.social previews three hot Education Program sessions.

🔗Innovation to Integration: The Next Phase of Immunotherapies in Myeloma, Leukemia, and Lymphoma: ow.ly/Y4lo50XvNLB #lymsm #leusm #mmsm #HemeSky #MedSky

5/6

📰 Your official #ASH25 news is here! The preview issue of #ASHNewsDaily is now live, with teasers of some can’t-miss sessions. 🧵

First up: Editor-in-Chief Joselle Cook, MBBS, welcomes you to the annual meeting! 🔗 ow.ly/IU2J50XvNOY #HemeSky #MedSky

1/6

Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines

Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...

The Trump administration is turning drug review into make-a-deal “FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts warn.

Discussion of FDAs new super-rapid review process and criteria to get such rapid reviews. www.statnews.com/2025/11/21/f... via @statnews.com

F.D.A. Names Agency Veteran to Run Drug Division

F.D.A. Names Agency Veteran to Run Drug Division www.nytimes.com/2025/11/11/s...

Artificial intelligence in hematology In the last 2 years, the capabilities of artificial intelligence (AI) have progressed rapidly and are increasingly being integrated into hematology practic

Artificial intelligence in hematology url: ashpublications.org/blood/articl...

Hopefully on my way to Alliance meeting in Chicago- look forward to Transplant and Cellular Based Therapies Committee tomorrow

A team at MSK is shedding new light on #VEXAS syndrome, a severe autoinflammatory condition arising from a mutation in the UBA1 gene.

“We are hopeful that the therapeutic targets identified by our research can pave the way for new approaches.” says @gitlinlabmsk.bsky.social.

bit.ly/4oRQ5LF

‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say

‘Intentional’ Explosion Took Place at Harvard Medical School, Officials Say www.nytimes.com/2025/11/01/u...

Great meeting with friends and colleagues to discuss chronic GVHD last week in Detroit with Steven Pavletic, Daniel Couriel, Corey Cutler, Stephanie Lee & Stefanie Sarantopoulos